
Overview

Useful For

Assessment of possible adulteration of a urine specimen submitted for drug of abuse testing

Providing the creatinine concentration for normalization purposes

Testing Algorithm

See [Adulterant Survey Algorithm](#) in Special Instructions.

Special Instructions

- [Adulterant Survey Algorithm](#)

Method Name

Spectrophotometry (SP)

NY State Available

Yes

Specimen

Specimen Type

Urine

Specimen Required

Container/Tube: Plastic, 60-mL urine bottle

Specimen Volume: 1.5 mL

Collection Instructions:

1. Collect a random urine specimen.
2. No preservative.

Additional Information:

1. For situations where chain of custody is required, a Chain-of-Custody Kit (T282) is available. For chain-of-custody information, see ADLTX / Adulterants Survey, Chain of Custody, Random, Urine.

2. Submitting less than 1.5 mL may compromise the ability to perform all necessary testing.

Forms

If not ordering electronically, complete, print, and send a [Therapeutics Test Request](#) (T831) with the specimen.

Reject Due To

All specimens will be evaluated at Mayo Clinic Laboratories for test suitability.

Specimen Minimum Volume

1 mL

Specimen Stability Information

| Specimen Type | Temperature | Time | Special Container |
|---------------|--------------------------|---------|-------------------|
| Urine | Refrigerated (preferred) | 14 days | |
| | Frozen | 14 days | |
| | Ambient | | |

Clinical & Interpretive**Clinical Information**

Specimen adulteration is the manipulation of a sample that may cause falsely negative test results for the presence of drugs of abuse. Common adulterants that may affect testing are water, soap, bleach, vinegar, oxidants, and salt. The adulteration testing includes assessment of creatinine concentration, pH, urine specific gravity, presence or absence of an oxidant, and presence or absence of nitrite.

Reference Values

Cutoff concentrations

Oxidants: 200 mg/L

Nitrites: 500 mg/L

Interpretation

See [Adulterant Survey Algorithm](#) in Special Instructions.

Cautions

No significant cautionary statements

Clinical Reference

1. US Department of Health and Human Services, Substance Abuse and Mental Health Services Administration (SAMHSA): Mandatory Guidelines for Federal Workplace Drug Testing Programs. Federal Register. 2017 January 23;82(13):FR 7920. Available at: www.samhsa.gov/sites/default/files/workplace/frn_vol_82_7920_.pdf
2. US Department of Health and Human Services, Substance Abuse and Mental Health Services Administration (SAMHSA): Drug-Free Workplace Guidelines and Resources Updated June 7, 2021. Accessed September 27, 2021. Available at: www.samhsa.gov/workplace/resources

Performance**Method Description**

All results are measured using spectrophotometry at wavelengths specified by the reagent manufacturer. The use of a refractometer may also be used in the specific gravity measurement. (Package inserts: Creatinine plus ver 2, Specimen Validity Test Nitrite, Specimen Validity Test Oxidant, Specimen Validity Test pH, Specimen Validity Test Specific Gravity. Roche Diagnostics; 12/2016)

PDF Report

No

Specimen Retention Time

2 weeks

Performing Laboratory Location

Rochester

Fees & Codes**Test Classification**

This test has been cleared, approved, or is exempt by the US Food and Drug Administration and is used per manufacturer's instructions. Performance characteristics were verified by Mayo Clinic in a manner consistent with CLIA requirements.

CPT Code Information

81005

LOINC® Information

| Test ID | Test Order Name | Order LOINC Value |
|---------|-----------------------|-------------------|
| ADULT | Adulterants Survey, U | 58714-7 |

| Result ID | Reporting Name | LOINC® |
|-----------|------------------|---------|
| 20606 | Creatinine, U | 2161-8 |
| 22312 | Specific Gravity | 5810-7 |
| 23509 | pH | 2756-5 |
| 23511 | Oxidants | 58714-7 |
| 23510 | Nitrites | 32710-6 |
| 30914 | Comment | 48767-8 |